Heidelberg Pharma Signs License Agreement with The University of Texas MD Anderson Cancer Center
Heidelberg Pharma AG today announced the signing of a license agreement between its affiliate, Heidelberg Pharma Research GmbH and The University of Texas System, on behalf of MD Anderson Cancer Center (MD Anderson), for patent rights related to the diagnosis and treatment of patients with RNA polymerase II deletion.